Geron Corporation (GERN)vsNovartis AG ADR (NVS)
GERN
Geron Corporation
$0.89
-5.47%
HEALTHCARE · Cap: $745.27M
NVS
Novartis AG ADR
$160.79
-0.19%
HEALTHCARE · Cap: $303.67B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 27943% more annual revenue ($57.36B vs $204.56M). NVS leads profitability with a 17.5% profit margin vs -33.1%. NVS earns a higher WallStSmart Score of 48/100 (D+).
GERN
Avoid32
out of 100
Grade: F
NVS
Hold48
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for GERN.
Margin of Safety
-68.3%
Fair Value
$95.56
Current Price
$160.79
$65.23 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
17.2% revenue growth
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Strong operational efficiency at 34.3%
Generating 5.6B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -32.0% — below average capital efficiency
Premium valuation, high expectations priced in
Trading at 8.2x book value
4.7% revenue growth
Grey zone — moderate risk
Comparative Analysis Report
WallStSmart ResearchBull Case : GERN
The strongest argument for GERN centers on Price/Book, Revenue Growth. Revenue growth of 17.2% demonstrates continued momentum.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.5% and operating margin at 34.3%.
Bear Case : GERN
The primary concerns for GERN are EPS Growth, Market Cap, Piotroski F-Score.
Bear Case : NVS
The primary concerns for NVS are P/E Ratio, Price/Book, Revenue Growth.
Key Dynamics to Monitor
GERN profiles as a growth stock while NVS is a value play — different risk/reward profiles.
GERN carries more volatility with a beta of 0.61 — expect wider price swings.
GERN is growing revenue faster at 17.2% — sustainability is the question.
NVS generates stronger free cash flow (5.6B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (48/100 vs 32/100), backed by strong 17.5% margins. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Geron Corporation
HEALTHCARE · BIOTECHNOLOGY · USA
Geron Corporation, an advanced stage clinical biopharmaceutical company, focuses on the development and commercialization of therapies for myeloid hematologic neoplasms. The company is headquartered in Foster City, California.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?